humanization

The humanization of the sufferer The human quality of the sufferers in emergency news is semiotized as their capacity to act. The action of the sufferers has different visual manifestations. It may be visualized as motion, where the sufferer participates in concrete, purposeful activity; as gaze, where the sufferer enters into an active relationship with the camera; or as condition, where the sufferer symbolizes a ‘universal’ human state of existence

Die Humanisierung des Leidenden Der menschliche Qualität der Betroffenen in Not News als ihre Handlungsfähigkeit semiotized. Die Wirkung der Betroffenen hat verschiedene visuelle Manifestationen. Es kann sein, visualisiert als Bewegung, wo der Leidende beteiligt sich an konkreten, zielgerichteten Aktivität, wie Blick, wo der Leidende tritt in eine aktive Beziehung mit der Kamera, oder als Bedingung, wo der Leidende symbolisiert eine "universelle" menschlichen Zustand der Existenz

OP preparation for the determination of-tumor cells (e.g. edge of removal, ensuring the extent of resection) Lymph nodes for the detection of metastases and tumor cells (“microenvolvement”) Lavage for the determination of disseminated tumor cells in the peritoneal cavity Tissue for the determination of disseminated tumor cells (immunohistochemistry) Differential diagnosis of carcinomas immunohistochemical determination of characteristic E-cadherin mutations for differential diagnostic evaluation of suspected tissue samples Screening of high-risk groups (“cancer families”) determination of E-cadherin mutations in blood cells (DNA) in vivo Prerequisite: humanization of the antibody for therapeutic use specific determination of tumor cells by immunoscintigraphy: pre-therapeutically for set up of operation plan/therapy plan for the control of the course of therapy or, respectively, for the verification of a successful therapy and for the control of the post-therapeutical course of the disease Therapy by mutation-specific E-cadherin antibodies: immunoradiotherapy coupling of a source of radiation to the mutation-specific antibody immunotoxin therapy coupling of a toxin (e.g. pseudomonas toxin) to the antibody Somatic gene therapy by mutation-specific E-cadherin antibodies: possible ways for a specific gene transfer: coupling to viral gene expression systems (e.g. adenovirus, or MVA, vaccinia-derived expression vectors); coupling to non-viral gene expression systems (e.g. T7 RNA polymerase+T7 DNA vector); Possible therapy approach using genetic engineering: incorporation of cofactors (e.g. B7) to label the tumor cells for the endogenous immune system; incorporation of alloantigens (foreign HLA antigens, “major antigens”) to activate the endogenous T cells and initiate an immune reaction against tumor cells having mutated E-cadherin “minor antigen”); killing of tumor cells by specific incorporation of factors inducing apoptosis (e.g. p53); conversion of the malignant phenotype by specific incorporation of wildtype oncogenes/suppressor genes (e.g. E-cadherin itself); activation of a protoxin to form a toxin by specific inclusion of an enzyme (e.g. cytosin deaminase, conversion of 5-fluoro cytosin into the toxic 5-fluoro uracil); Ribozymes e.g. site-specific destruction of the RNA coding for the multidrug-resistance transporter Further examples showing fields of use of the E-cadherin mutations bone marrow purching: specific determination of tumor cells in treated bone marrow in vitro and concurrent use of the antibody for specific elimination of tumor cells from the bone marrow (e.g. by a toxin bound to the antibody); immune therapy charging of dendritic cells with mutated E-cadherin peptide sequences (see Table 3) for antigen presentation (activation of T cell clones specifically directed against tumor cells).

Prospektive Untersuchung in vitro von Therapie mittels mutations-spezifischer E-Cadherin Antikörper: Somatische Gentherapie mittels mutations-spezifischer E-Cadherin Antikörper: Weitere Beispiele von Anwendungsbereichen der E-Cadherin Mutationen Beim intrazellulären Abbau von Proteinen entstehen Peptide mit unterschiedlicher Länge.